This was clinically validated in a phase Ib/II clinical trial treating 38 patients with PD-L1-naïve advanced solid tumours and recurrent/metastatic head and neck cancer with danvatirsen combined with durvalumab (an anti-PD-L1 antibody) as second-line treatment (NCT02499328) [98]. This evidence concerns the gene CD274 and head and neck cancer.